Association of body composition and systemic inflammation for patients with locally advanced cervical cancer following concurrent chemoradiotherapy

被引:0
|
作者
Li, Juan [1 ]
Niu, Cuili [1 ]
Zhang, Ling [1 ]
Mu, Yanmin [1 ]
Gui, Xiuyin [1 ]
机构
[1] Xingtai Third Hosp, Clin Gynecol, Xingtai, Peoples R China
来源
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY | 2024年 / 30卷 / 05期
关键词
Cervical cancer; concurrent chemoradiotherapy; systemic inflammation; body composition; prognosis; VISCERAL FAT PERCENTAGE; PROGNOSTIC VALUE; SARCOPENIA; OBESITY; PREDICTION; MARKERS; CELLS;
D O I
10.4274/dir.2024.242751
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE Systemic inflammation and body composition are associated with survival outcomes of cancer patients. This study aimed to examine the combined prognostic value of systemic inflammatory markers and body composition parameters in patients with locally advanced cervical cancer (LACC). METHODS Patients who underwent concurrent chemoradiotherapy (CCRT) for LACC at a tertiary referral teaching hospital between January 2010 and January 2018 were enrolled. A predictive model was established based on systemic immune-inflammation index (SII) and computer tomography-derived visceral fat-to-muscle ratio (vFMR). Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method and Cox regression models. The model performance was assessed using discrimination, calibration, and clinical usefulness. RESULTS In total, 212 patients were enrolled. The SII and vFMR were closely related, and both independently predicted survival (P < 0.05). A predictive model was established based on the above biomarkers and included three subgroups: high-risk [both high SII (>828) and high vFMR (>1.1)], middle-risk (either high SII or high vFMR), and low-risk (neither high SII nor high vFMR). The 3-year OS (PFS) rates for low-, middle-, and high-risk patients were 90.5% (86.0%), 73.9% (58.4%), and 46.8% (36.1%), respectively (P < 0.05). This model demonstrated satisfactory predictive accuracy (area under the curve values for predicting 3-year OS and PFS were 0.704 and 0.718, respectively), good fit (Hosmer-Lemeshow tests: P > 0.05), and clinical usefulness. CONCLUSION Systemic inflammatory markers combined with body composition parameters could independently predict the prognosis of patients with LACC, highlighting the utilization of commonly collected indicators in decision-making processes.
引用
收藏
页码:279 / 290
页数:12
相关论文
共 50 条
  • [41] Benefits of docetaxel and lobaplatin combined with concurrent chemoradiotherapy for locally advanced breast cancer
    Li, Wei
    Jiang, Li
    Zeng, Xiaohua
    Wu, Jing
    Jiang, Geli
    Pan, Xianjun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (05): : 5794 - 5802
  • [42] Association between body composition phenotypes and treatment toxicity in women with cervical cancer undergoing chemoradiotherapy
    Aredes, Mariah Azevedo
    de Paula, Nathalia Silva
    Chaves, Gabriela Villaca
    NUTRITION, 2024, 127
  • [43] Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy
    Kiyotoki, Takanori
    Nakamura, Keiichiro
    Haraga, Junko
    Omichi, Chiaki
    Ida, Naoyuki
    Saijo, Masayuki
    Nishida, Takeshi
    Kusumoto, Tomoyuki
    Masuyama, Hisashi
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (01) : 168 - 175
  • [44] Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer
    Ren, Hu
    Zhang, Jian-Wei
    Lan, Zhong-Min
    Du, Yong-Xing
    Qiu, Guo-Tong
    Zhang, Li-Peng
    Gu, Zong-Ting
    Li, Zong-Ze
    Li, Guang
    Shao, Hai-Bo
    Ju, Zhong-Jian
    Yu, Wei
    Qu, Bao-Lin
    Xu, Ke
    Wang, Cheng-Feng
    PANCREATOLOGY, 2021, 21 (06) : 1052 - 1058
  • [45] Response to concurrent chemoradiotherapy as a prognostic marker in elderly patients with locally advanced esophageal cancer
    Go, Se-Il
    Lee, Won Sup
    Kang, Myung Hee
    Song, Haa-Na
    Kim, Moon Jin
    Lee, Min Jeong
    Kim, Hoon-Gu
    Lee, Gyeong Won
    Kang, Jung Hun
    Lee, Jeong-Hee
    Kang, Ki Mun
    Jeon, Kyung-Nyeo
    Cho, Jae Min
    Jung, Woon Tae
    Ko, Gyung Hyuck
    TUMORI, 2012, 98 (02) : 225 - 232
  • [46] Concurrent Chemoradiotherapy in Elderly Patients with Locally Advanced Esophageal Carcinoma
    Jung, Bae Kwon
    Kang, Ki Mun
    Lee, Gyeong Won
    Kang, Jung Hoon
    Kim, Hoon Gu
    Lee, Won Seob
    Chai, Gyu Young
    RADIATION ONCOLOGY JOURNAL, 2009, 27 (02): : 84 - 90
  • [47] A comparative study of nab-paclitaxel versus cisplatin concurrent chemoradiotherapy in locally advanced cervical cancer
    Mandloi, Varsha
    Yogi, Veenita
    Singh, Om Prakash
    Ahirwar, Manish Kumar
    Yadav, Suresh
    Ghori, H. U.
    CLINICAL CANCER INVESTIGATION JOURNAL, 2019, 8 (05): : 198 - 204
  • [48] The combination of body composition conditions and systemic inflammatory markers has prognostic value for patients with gastric cancer treated with adjuvant chemoradiotherapy
    Li, Yi
    Wang, Wen-bo
    Yang, Lei
    Wang, Qing-yun
    Dai, Jing
    Xia, Ling
    Peng, Jin
    Zhou, Fu-xiang
    Wei, Yong-chang
    Shi, Han-ping
    NUTRITION, 2022, 93
  • [49] Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study
    Lim, Hyunji
    Kim, Se Ik
    Kim, Min Kyung
    Yoon, Soon Ho
    Lee, Maria
    Suh, Dong Hoon
    Kim, Hee Seung
    Kim, Kidong
    No, Jae Hong
    Chung, Hyun Hoon
    Kim, Yong Beom
    Park, Noh Hyun
    Kim, Jae-Weon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : 200 - 208
  • [50] Association between IVIM parameters and treatment response in locally advanced squamous cell cervical cancer treated by chemoradiotherapy
    Perucho, Jose Angelo Udal
    Wang, Mandi
    Vardhanabhuti, Varut
    Tse, Ka Yu
    Chan, Karen Kar Loen
    Lee, Elaine Yuen Phin
    EUROPEAN RADIOLOGY, 2021, 31 (10) : 7845 - 7854